Comparing Clopidogrel and Cilostazol in Type 2 Diabetes Patients With Carotid Atherosclerosis

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Diabetes is an increasing cause of atherosclerotic and cardiovascular illnesses in South Korea. The clinical application of ultrasound for measuring carotid intima-media thickness, which helps in early detection and surveillance of atherosclerosis, is advancing. Due to lifestyle changes and an aging population, Koreans, especially diabetics, are developing more vascular diseases and are at higher risk for peripheral vascular disorders. Diabetics with lower limb peripheral artery disease require effective therapy to avoid major complications and a reduced quality of life. Although licensed for symptom control, Clopidogrel and Cilostazol have not yet been established for primary prevention of cardiovascular risks. These medications will be evaluated for their potential as primary preventive agents against cardiovascular disease in type 2 diabetes patients. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and to evaluate their influence on hemorheological changes in individuals with Type 2 diabetes. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and evaluating their influence on alterations in blood flow among individuals with Type 2 diabetes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:

• Adults with diabetes aged 19 and older

• Individuals with a carotid ultrasound cIMT (carotid intima-media thickness) of 1.0mm or more

• Those who have not changed their combination therapy medications (including oral hypoglycemics, antihypertensives, and lipid-lowering drugs) in the last three months

• Individuals with an HbA1c level of 10% or less

• Those who have voluntarily signed the written consent form and agreed to participate in the study

Locations
Other Locations
Republic of Korea
Seoul National University Bundang Hospital
RECRUITING
Seongnam-si
Contact Information
Primary
Soo Lim, MD. Ph.D.
limsoo@snu.ac.kr
+82317877035
Backup
Minji Sohn, Ph.D.
rainbowmjs@naver.com
+82317878443
Time Frame
Start Date: 2024-04-16
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 120
Treatments
Experimental: Clopidogrel
Clopidogrel 75mg once daily
Active_comparator: Cilostazol
Cilostazol 200mg per day
Sponsors
Collaborators: Samjin Pharmaceutical Co., Ltd.
Leads: Seoul National University Bundang Hospital

This content was sourced from clinicaltrials.gov